

Magle Group contemplates issuance of senior secured bonds

Magle Chemoswed Holding AB (publ) ("Magle Group") has mandated Pareto Securities AB ("Pareto") to arrange a series of investor meetings commencing on 16 June 2025 to explore the possibility of issuing SEK denominated senior secured floating rate bonds with a tenor of three years and with an initial issue amount of up to SEK 300 million within a framework of SEK 450 million. A capital markets transaction may follow, subject to *inter alia* market conditions.

The net proceeds from the contemplated bond issue will be used to refinance existing debt and finance general corporate purposes, including investments, acquisitions and capital expenditure.

As part of the preparations for the contemplated bond issue, Magle Group has complied and hereby publishes selected consolidated financial information for the group per 31 March 2025.

As per 31 March 2025, last twelve months' EBITDA, pro forma for completed acquisitions and run-rate effect of savings from subsequently implemented cost initiatives, amounted to SEK 84 million, and pro forma net debt amounted to SEK 333 million.

Advokatfirman Schjødt acts as legal advisor to Magle Group, Vator Securities acts as financial advisor to Magle Group and Roschier Advokatbyrå acts as legal advisor to Pareto Securities in connection with the bond issue.

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-13 07:30 CEST.

Attachments

[Magle Group contemplates issuance of senior secured bonds](#)